<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE - amiloride hydrochloride and hydrochlorothiazide tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<a href="http://"></a><p class="First">Like other potassium-conserving diuretic combinations, amiloride 
and hydrochlorothiazide may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium levels greater 
than 5.5 mEq per liter). In patients without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 
mellitus, the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> with this combination product is about 1 to 2 
percent. This risk is higher in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 
mellitus (even without recognized <span class="product-label-link" type="condition" conceptid="192279" conceptname="Diabetic renal disease">diabetic nephropathy</span>). Since <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, if 
uncorrected, is potentially fatal, it is essential to monitor serum potassium 
levels carefully in any patient receiving amiloride hydrochloride and 
hydrochlorothiazide, particularly when it is first introduced, at the time of 
dosage adjustments, and during any illness that could affect renal 
function.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Amiloride hydrochloride and hydrochlorothiazide tablets combine 
the potassium-conserving action of amiloride hydrochloride with the natriuretic 
action of hydrochlorothiazide.</p>
<p>Amiloride HCl is designated chemically as 3,5-diamino-6-chloro-<span class="Italics">N</span>-(diaminomethylene)pyrazinecarboxamide monohydrochloride, 
dihydrate. It has the following structural formula:</p>
<p><img alt="image of chemical structure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71f5c703-94d4-49b0-9c2d-374b9cbcab85&amp;name=chemical%20structure%201.jpg"></p>
<p>C<span class="Sub">6</span>H<span class="Sub">8</span>ClN<span class="Sub">7</span>O•HCl•2H<span class="Sub">2</span>O                   MW = 302.12</p>
<p>Hydrochlorothiazide is designated chemically as 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. It has 
the following structural formula:</p>
<p><img alt="image of chemical structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71f5c703-94d4-49b0-9c2d-374b9cbcab85&amp;name=chemical%20structure.jpg"></p>
<p>C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span>                  MW = 297.74</p>
<p>It is a white, or practically white, crystalline powder which is slightly 
soluble in water, but freely soluble in sodium hydroxide solution.</p>
<p>Each tablet, for oral administration, contains 5 mg of amiloride 
hydrochloride (calculated on the anhydrous basis) and 50 mg of 
hydrochlorothiazide. In addition, each tablet contains the following inactive 
ingredients: croscarmellose sodium, lactose (hydrous), magnesium stearate, 
pregelatinized starch, sodium lauryl sulfate, and FD&amp;C Yellow #6 Aluminum 
Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Amiloride hydrochloride and hydrochlorothiazide tablets provide 
diuretic and antihypertensive activity (principally due to the 
hydrochlorothiazide component), while acting through the amiloride component to 
prevent the excessive potassium loss that may occur in patients receiving a 
thiazide diuretic. Due to its amiloride component, the urinary excretion of 
magnesium is less with amiloride and hydrochlorothiazide than with a thiazide or 
loop diuretic used alone (see <a href="#section-8">PRECAUTIONS</a>). The onset 
of the diuretic action of this product is within 1 to 2 hours and this action 
appears to be sustained for approximately 24 hours.</p>
<a href="http://"></a><a href="http://"></a>Amiloride hydrochloride<p>Amiloride hydrochloride is a potassium-conserving 
(antikaliuretic) drug that possesses weak (compared with thiazide diuretics) 
natriuretic, diuretic, and antihypertensive activity. These effects have been 
partially additive to the effects of thiazide diuretics in some clinical 
studies. Amiloride HCl has potassium-conserving activity in patients receiving 
kaliuretic-diuretic agents.</p>
<p>Amiloride HCl is not an aldosterone antagonist and its effects are seen even 
in the absence of aldosterone.</p>
<p>Amiloride HCl exerts its potassium sparing effect through the inhibition of 
sodium reabsorption at the distal convoluted tubule, cortical collecting tubule 
and collecting duct; this decreases the net negative potential of the tubular 
lumen and reduces both potassium and hydrogen secretion and their subsequent 
excretion. This mechanism accounts in large part for the potassium sparing 
action of amiloride.</p>
<p>Amiloride HCl usually begins to act within 2 hours after an oral dose. Its 
effect on electrolyte excretion reaches a peak between 6 to 10 hours and lasts 
about 24 hours. Peak plasma levels are obtained in 3 to 4 hours and the plasma 
half-life varies from 6 to 9 hours. Effects on electrolytes increase with single 
doses of amiloride hydrochloride up to approximately 15 mg.</p>
<p>Amiloride HCl is not metabolized by the liver but is excreted unchanged by 
the kidneys. About 50 percent of a 20 mg dose of amiloride hydrochloride is 
excreted in the urine and 40 percent in the stool within 72 hours. Amiloride HCl 
has little effect on glomerular filtration rate or renal blood flow. Because 
amiloride HCl is not metabolized by the liver, drug accumulation is not 
anticipated in patients with hepatic dysfunction, but accumulation can occur if 
the <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span> develops.</p>
<a href="http://"></a><a href="http://"></a>Hydrochlorothiazide<p>The mechanism of the antihypertensive effect of thiazides is 
unknown. Thiazides do not usually affect normal blood pressure.</p>
<p>Hydrochlorothiazide is a diuretic and antihypertensive. It affects the distal 
renal tubular mechanism of electrolyte reabsorption. Hydrochlorothiazide 
increases excretion of sodium and chloride in approximately equivalent amounts. 
Natriuresis may be accompanied by some loss of potassium and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>After oral use <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within two hours, peaks in about four hours 
and lasts about 6 to 12 hours.</p>
<p>Hydrochlorothiazide is not metabolized but is eliminated rapidly by the 
kidney. When plasma levels have been followed for at least 24 hours, the plasma 
half-life has been observed to vary between 5.6 and 14.8 hours. At least 61 
percent of the oral dose is eliminated unchanged within 24 hours. 
Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is 
excreted in breast milk.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Amiloride hydrochloride and hydrochlorothiazide tablets are 
indicated in those patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> 
who develop <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> when thiazides or other kaliuretic diuretics are used 
alone, or in whom maintenance of normal serum potassium levels is considered to 
be clinically important, e.g., digitalized patients, or patients with 
significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>The use of potassium-conserving agents is often unnecessary in patients 
receiving diuretics for uncomplicated <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> when such patients 
have a normal diet.</p>
<p>Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or 
as an adjunct to other antihypertensive drugs, such as methyldopa or beta 
blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the 
action of these agents, dosage adjustments may be necessary to avoid an 
excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> and other unwanted side effects.</p>
<p><span class="Bold">This fixed combination drug is not indicated for the initial 
therapy of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> except in individuals in whom the development 
of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> cannot be risked.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span><p class="First">Amiloride hydrochloride and hydrochlorothiazide tablets should 
not be used in the presence of elevated serum potassium levels (greater than 5.5 
mEq per liter).</p>
<a href="http://"></a><a href="http://"></a>Antikaliuretic Therapy or Potassium 
Supplementation<p>Amiloride hydrochloride and hydrochlorothiazide should not be 
given to patients receiving other potassium-conserving agents, such as 
spironolactone or triamterene. Potassium supplementation in the form of 
medication, potassium-containing salt substitutes or a potassium-rich diet 
should not be used with this product except in severe and/or refractory cases of 
<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Such concomitant therapy can be associated with rapid increases in 
serum potassium levels. If potassium supplementation is used, careful monitoring 
of the serum potassium level is necessary.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span><p><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, acute or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span>, and evidence of 
<span class="product-label-link" type="condition" conceptid="192279" conceptname="Diabetic renal disease">diabetic nephropathy</span> are contraindications to the use of amiloride hydrochloride 
and hydrochlorothiazide. Patients with evidence of renal functional impairment 
(blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine 
levels over 1.5 mg per 100 mL) or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus should not receive the drug 
without careful, frequent and continuing monitoring of serum electrolytes, 
creatinine, and BUN levels. Potassium retention associated with the use of an 
antikaliuretic agent is accentuated in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and may 
result in the rapid development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span><p>Amiloride hydrochloride and hydrochlorothiazide tablets are 
contraindicated in patients who are hypersensitive to this product, or to other 
sulfonamide-derived drugs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span><a href="http://"></a><a href="http://"></a><p class="First">Like other potassium-conserving diuretic combinations, amiloride 
and hydrochlorothiazide may cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium levels greater 
than 5.5 mEq per liter). In patients without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 
mellitus, the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> with this combination product is about 1 to 2 
percent. This risk is higher in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 
mellitus (even without recognized <span class="product-label-link" type="condition" conceptid="192279" conceptname="Diabetic renal disease">diabetic nephropathy</span>). Since <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, if 
uncorrected, is potentially fatal, it is essential to monitor serum potassium 
levels carefully in any patient receiving amiloride hydrochloride and 
hydrochlorothiazide, particularly when it is first introduced, at the time of 
dosage adjustments, and during any illness that could affect renal 
function.</p>
<a href="http://"></a><a href="http://"></a><p>The risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be increased when 
potassium-conserving agents, including amiloride hydrochloride and 
hydrochlorothiazide, are administered concomitantly with an 
angiotensin-converting enzyme inhibitor, cyclosporine or tacrolimus. (See <a href="#section-8.2">PRECAUTIONS: Drug Interactions</a>.) Warning signs or 
symptoms of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, 
<span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span> of the extremities, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and ECG abnormalities. 
Monitoring of the serum potassium level is essential because mild <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> 
is not usually associated with an <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">abnormal ECG</span>.</p>
<p>When abnormal, the ECG in <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is characterized primarily by tall, 
peaked T waves or elevations from previous tracings. There may also be lowering 
of the R wave and increased depth of the S wave, widening and even disappearance 
of the P wave, progressive widening of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span>, prolongation of the PR 
interval, and ST <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<a href="http://"></a><a href="http://"></a>Treatment of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span><p>If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> occurs in patients taking amiloride and 
hydrochlorothiazide, the drug should be discontinued immediately. If the serum 
potassium level exceeds 6.5 mEq per liter, active measures should be taken to 
reduce it. Such measures include the intravenous administration of sodium 
<span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> solution or oral or parenteral glucose with a rapid-acting insulin 
preparation. If needed, a cation exchange resin such as sodium polystyrene 
sulfonate may be given orally or by enema. Patients with persistent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> 
may require dialysis.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus<p>In diabetic patients, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> has been reported with the use 
of all potassium-conserving diuretics, including amiloride HCl, even in patients 
without evidence of <span class="product-label-link" type="condition" conceptid="192279" conceptname="Diabetic renal disease">diabetic nephropathy</span>. Therefore, amiloride and 
hydrochlorothiazide should be avoided, if possible, in diabetic patients and, if 
it is used, serum electrolytes and renal function must be monitored 
frequently.</p>
<p>Amiloride and hydrochlorothiazide should be discontinued at least three days 
before glucose tolerance testing.</p>
<a href="http://"></a><a href="http://"></a>Metabolic or <span class="product-label-link" type="condition" conceptid="4048509" conceptname="Respiratory acidosis">Respiratory Acidosis</span><p>Antikaliuretic therapy should be instituted only with caution in 
severely ill patients in whom respiratory or <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may occur, such 
as patients with cardiopulmonary disease or poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. If 
amiloride and hydrochlorothiazide is given to these patients, frequent 
monitoring of acid-base balance is necessary. Shifts in acid-base balance alter 
the ratio of extracellular/intracellular potassium, and the development of 
<span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> may be associated with rapid increases in serum potassium levels.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalance</span> and BUN Increases<p class="First">Determination of serum electrolytes to detect possible 
<span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p>Patients should be observed for clinical signs of fluid or electrolyte 
imbalance: i.e., <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum 
and urine electrolyte determinations are particularly important when the patient 
is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or 
symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause, include 
dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, 
<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, 
<span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and 
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span> may occur during the use of thiazides and 
other diuretics. Any chloride deficit during thiazide therapy is generally mild 
and may be lessened by the amiloride HCl component of this product. 
<span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">Hypochloremia</span> usually does not require specific treatment except under 
extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>). Dilutional 
<span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy 
is water restriction, rather than administration of salt, except in rare 
instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, 
appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop during thiazide therapy, especially with brisk 
<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present, during concomitant use of 
corticosteroids or ACTH, or after prolonged therapy. However, this usually is 
prevented by the amiloride hydrochloride component of this combination drug 
product.</p>
<p>Interference with adequate oral electrolyte intake will also contribute to 
<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and may also sensitize or 
exaggerate the response of the heart to the toxic effects of digitalis (e.g., 
increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; 
this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Amiloride hydrochloride, a component of this 
combination product, has been shown to decrease the enhanced urinary excretion 
of magnesium which occurs when a thiazide or loop diuretic is used alone.</p>
<p>Increases in BUN levels have been reported with amiloride hydrochloride and 
with hydrochlorothiazide. These increases usually have accompanied vigorous 
fluid elimination, especially when diuretic therapy was used in seriously ill 
patients, such as those who had <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> with <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> and metabolic 
<span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>, or those with resistant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Therefore, when amiloride and 
hydrochlorothiazide is given to such patients, careful monitoring of serum 
electrolyte and BUN levels is important. In patients with pre-existing severe 
liver disease, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, manifested by <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and 
<span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and increased <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, have been reported in association with diuretic 
therapy including amiloride HCl and hydrochlorothiazide.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, diuretics may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. 
Cumulative effects of the components of amiloride hydrochloride and 
hydrochlorothiazide may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. If 
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, amiloride and hydrochlorothiazide should be 
discontinued (see <a href="#section-6">CONTRAINDICATIONS</a> and <a href="#section-7">WARNINGS</a>).</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>In some patients, the administration of a non-steroidal 
anti-inflammatory agent can reduce the diuretic, natriuretic, and 
antihypertensive effects of loop, potassium-sparing and thiazide diuretics. 
Therefore, when amiloride and hydrochlorothiazide and non-steroidal 
anti-inflammatory agents are used concomitantly, the patient should be observed 
closely to determine if the desired effect of the diuretic is obtained. Since 
indomethacin and potassium-sparing diuretics, including this product, may each 
be associated with increased serum potassium levels, the potential effects on 
potassium kinetics and renal function should be considered when these agents are 
administered concurrently.</p>
<a href="http://"></a><a href="http://"></a>Amiloride HCl<p>When amiloride HCl is administered concomitantly with an 
angiotensin-converting enzyme inhibitor, cyclosporine or tacrolimus, the risk of 
<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be increased. Therefore, if concomitant use of these agents is 
indicated because of demonstrated <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, they should be used with caution 
and with frequent monitoring of serum potassium. (See <a href="#section-7">WARNINGS</a>.)</p>
<a href="http://"></a><a href="http://"></a>Hydrochlorothiazide<p>When given concurrently the following drugs may interact with 
thiazide diuretics.</p>
<p><span class="Italics">Alcohol, Barbiturates, or Narcotics:</span> Potentiation 
of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Antidiabetic Drugs (Oral Agents and Insulin):</span> 
Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics">Other Antihypertensive Drugs:</span> Additive effect or 
potentiation.</p>
<p><span class="Italics">Cholestyramine and Colestipol Resins:</span> Absorption 
of hydrochlorothiazide is impaired in the presence of anionic exchange resins. 
Single doses of either cholestyramine or colestipol resins bind the 
hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by 
up to 85 and 43 percent, respectively.</p>
<p><span class="Italics">Corticosteroids, ACTH:</span> Intensified electrolyte 
depletion, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Pressor Amines (e.g., Norepinephrine):</span> Possible 
decreased response to pressor amines but not sufficient to preclude their 
use.</p>
<p><span class="Italics">Skeletal Muscle Relaxants, Nondepolarizing (e.g., 
Tubocurarine):</span> Possible increased responsiveness to the muscle 
relaxant.</p>
<p><span class="Italics">Lithium:</span> Generally should not be given with 
diuretics. Diuretic agents reduce the renal clearance of lithium and add a high 
risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations 
before use of such preparations with this combination product.</p>
<a href="http://"></a><a href="http://"></a>Metabolic and Endocrine Effects<p>In diabetic patients, insulin requirements may be increased, 
decreased, or unchanged due to the hydrochlorothiazide component. <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> 
mellitus that has been latent may become manifest during administration of 
thiazide diuretics.</p>
<p>Because calcium excretion is decreased by thiazides, amiloride and 
hydrochlorothiazide should be discontinued before carrying out tests for 
parathyroid function. Pathologic changes in the parathyroid glands, with 
<span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on 
prolonged thiazide therapy; however, the common complications of 
<span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> such as renal lithiasis, bone resorption, and peptic 
ulceration have not been seen.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients 
receiving thiazide therapy.</p>
<a href="http://"></a><a href="http://"></a>Other Precautions<p>In patients receiving thiazides, sensitivity reactions may occur 
with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The possibility of 
exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported 
with the use of thiazides.</p>
<p>Increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels may be associated with 
thiazide diuretic therapy.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Long-term studies in animals have not been performed to evaluate 
the effects upon fertility, mutagenicity or carcinogenic potential of amiloride 
hydrochloride and hydrochlorothiazide.</p>
<a href="http://"></a><a href="http://"></a>Amiloride HCl<p>There was no evidence of a tumorigenic effect when amiloride 
hydrochloride was administered for 92 weeks to mice at doses up to 10 mg/kg/day 
(25 times the maximum daily human dose). Amiloride hydrochloride has also been 
administered for 104 weeks to male and female rats at doses up to 6 and 8 
mg/kg/day (15 and 20 times the maximum daily dose for humans, respectively) and 
showed no evidence of carcinogenicity.</p>
<p>Amiloride hydrochloride was devoid of mutagenic activity in various <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> 
of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> with or without a mammalian 
liver microsomal activation system (Ames test).</p>
<a href="http://"></a><a href="http://"></a>Hydrochlorothiazide<p>Two-year feeding studies in mice and rats conducted under the 
auspices of the National Toxicology Program (NTP) uncovered no evidence of a 
carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to 
approximately 600 mg/kg/day) or in male and female rats (at doses of up to 
approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for 
hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic <span class="Italics">in vitro</span> in 
the Ames mutagenicity assay of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster 
Ovary (CHO) test for chromosomal aberrations, or <span class="Italics">in 
vivo</span> in assays using mouse germinal cell chromosomes, Chinese Hamster 
bone marrow chromosomes, and the <span class="Italics">Drosophila</span> 
sex-linked recessive lethal trait gene. Positive test results were obtained only 
in the <span class="Italics">in vitro</span> CHO Sister Chromatid Exchange 
(clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using 
concentrations of hydrochlorothiazide from 43 to 1300 µg/mL, and in the <span class="Italics">Aspergillus nidulans</span> non-disjunction assay at an 
unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats 
of either sex in studies wherein these species were exposed, via their diet, to 
doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout 
gestation.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy<a href="http://"></a><a href="http://"></a>Teratogenic Effects. Pregnancy Category B<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies have been performed with combinations of 
amiloride hydrochloride and hydrochlorothiazide in rabbits and mice at doses up 
to 25 times the expected maximum daily dose for humans and have revealed no 
evidence of harm to the fetus. No evidence of impaired fertility in rats was 
apparent at dosage levels up to 25 times the expected maximum human daily dose. 
A perinatal and postnatal study in rats showed a reduction in maternal body 
<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during and after gestation at a daily dose of 25 times the expected 
maximum daily dose for humans. The body weights of alive pups at birth and at 
weaning were also reduced at this dose level. There are no adequate and 
well-controlled studies in pregnant women. Because animal reproduction studies 
are not always predictive of human responses, and because of the data listed 
below with the individual components, this drug should be used during pregnancy 
only if clearly needed.</p>
<a href="http://"></a><a href="http://"></a>Amiloride hydrochloride<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with amiloride hydrochloride in rabbits 
and mice given 20 and 25 times the maximum human dose, respectively, revealed no 
evidence of harm to the fetus, although studies showed that the drug crossed the 
placenta in modest amounts. Reproduction studies in rats at 20 times the 
expected maximum daily dose for humans showed no evidence of impaired fertility. 
At approximately 5 or more times the expected maximum daily dose for humans, 
some toxicity was seen in adult rats and rabbits and a decrease in rat pup 
growth and survival occurred.</p>
<a href="http://"></a><a href="http://"></a>Hydrochlorothiazide<a href="http://"></a><a href="http://"></a>Teratogenic Effects<p>Studies in which hydrochlorothiazide was orally administered to 
pregnant mice and rats during their respective periods of major organogenesis at 
doses up to 3000 and 1000 mg hydrochlorothiazide/ kg, respectively, provided no 
evidence of harm to the fetus. There are, however, no adequate and 
well-controlled studies in pregnant women.</p>
<a href="http://"></a><a href="http://"></a>Nonteratogenic Effects<p>Thiazides cross the placental barrier and appear in cord blood. 
There is a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly 
other adverse reactions that have occurred in adults.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Studies in rats have shown that amiloride is excreted in milk in 
concentrations higher than those found in blood, but it is not known whether 
amiloride HCl is excreted in human milk. However, thiazides appear in breast 
milk. Because of the potential for serious adverse reactions in nursing infants, 
a decision should be made whether to discontinue nursing or to discontinue the 
drug, taking into account the importance of the drug to the mother.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>Safety and effectiveness in pediatric patients have not been 
established.</p>
<a href="http://"></a><a href="http://"></a>Geriatric Use<p>Clinical studies of amiloride hydrochloride and 
hydrochlorothiazide tablets did not include sufficient numbers of subjects aged 
65 and over to determine whether they responded differently from younger 
subjects. Other reported clinical experience has not identified differences in 
responses between the elderly and younger patients. In general, dose selection 
for an elderly patient should be cautious, usually starting at the low end of 
the dosing range, reflecting the greater frequency of decreased hepatic, renal 
or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk 
of toxic reactions to this drug may be greater in patients with impaired renal 
function. Because elderly patients are more likely to have decreased renal 
function, care should be taken in dose selection, and it may be useful to 
monitor renal function. (See <a href="#section-6.3">CONTRAINDICATIONS: Impaired 
Renal Function</a>.)</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Amiloride hydrochloride and hydrochlorothiazide is usually well 
tolerated and significant clinical adverse effects have been reported 
infrequently. The risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium levels greater than 5.5 
mEq per liter) with amiloride hydrochloride and hydrochlorothiazide is about 1 
to 2 percent in patients without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (see 
WARNINGS). Minor adverse reactions to amiloride hydrochloride have been reported 
relatively frequently (about 20%) but the relationship of many of the reports to 
amiloride HCl is uncertain and the overall frequency was similar in 
hydrochlorothiazide treated groups. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, 
and mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> have been reported and probably are related to amiloride. 
Other adverse experiences that have been reported with amiloride and 
hydrochlorothiazide are generally those known to be associated with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, 
thiazide therapy, or with the underlying disease being treated. Clinical trials 
have not demonstrated that combining amiloride and hydrochlorothiazide increases 
the risk of adverse reactions over those seen with the individual 
components.</p>
<p>The adverse reactions for amiloride and hydrochlorothiazide listed in the 
following table have been arranged into two groups: (1) incidence greater than 
one percent; and (2) incidence one percent or less. The incidence for group (1) 
was determined from clinical studies conducted in the United States (607 
patients treated with amiloride and hydrochlorothiazide). The adverse effects 
listed in group (2) include reports from the same clinical studies and voluntary 
reports since marketing. The probability of a causal relationship exists between 
amiloride and hydrochlorothiazide and these adverse reactions, some of which 
have been reported only rarely.</p>
<a name="i061738db-c9cc-40b1-8867-905c81a50230"></a><table width="50%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th align="left">Incidence &gt;1%</th>
<th align="left">Incidence ≤ 1%</th>
</tr></thead>
<tbody>
<tr class="First"><td align="left"><span class="Italics">Body as a Whole</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><a href="#footnote-1">*</a>
</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span><a href="#footnote-1">*</a>
</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span><br><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
</tr>
<tr><td align="left"><span class="Italics">Cardiovascular</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span><br><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digitalis toxicity</span><br>Orthostatic 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span><br><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span></td>
</tr>
<tr><td align="left"><span class="Italics">Digestive</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span><a href="#footnote-1">*</a>
</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span></td>
<td align="left">GI disturbance</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="left">Appetite changes<br>Abdominal 
fullness<br><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span><br><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span><br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span><br><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
</tr>
<tr><td align="left"><span class="Italics">Metabolic</span></td></tr>
<tr>
<td align="left">  Elevated serum</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span></td>
</tr>
<tr>
<td align="left">  potassium levels</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
</tr>
<tr>
<td align="left">  (&gt; 5.5 mEq per liter)<a href="#footnote-2">†</a>
</td>
<td align="left">Symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span><a href="#footnote-3">‡</a>
</td>
</tr>
<tr><td align="left"><span class="Italics">Musculoskeletal</span></td></tr>
<tr>
<td align="left">  Leg <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">ache</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>/spasm<br><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint Pain</span></td>
</tr>
<tr><td align="left"><span class="Italics">Nervous</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><a href="#footnote-1">*</a>
</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>/<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span><br><span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span><br><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
</tr>
<tr><td align="left"><span class="Italics">Psychiatric</span></td></tr>
<tr>
<td align="left">  None</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span><br><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span><br><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span><br>Mental 
<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></td>
</tr>
<tr><td align="left"><span class="Italics">Respiratory</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="left">None</td>
</tr>
<tr><td align="left"><span class="Italics">Skin</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><a href="#footnote-1">*</a>
</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="left"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Diaphoresis</span><br><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> including<br>  Stevens-Jonhson 
syndrome<br><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> including<br>  toxic epidermal 
necrolysis<br><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
</tr>
<tr><td align="left"><span class="Italics">Special Senses</span></td></tr>
<tr>
<td align="left">  None</td>
<td align="left">Bad taste<br><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbance</span><br><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
</tr>
<tr><td align="left"><span class="Italics">Urogenital</span></td></tr>
<tr class="Last">
<td align="left">  None</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span><br><span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span><br><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span><br><span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span><br>Renal 
dysfunction including<br>  renal 
failure<br><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></td>
</tr>
</tbody>
</table>
<a href="#footnote-reference-1">*</a>Reactions occurring in 3% to 8% of patients treated with amiloride 
hydrochloride and hydrochlorothiazide. (Those reactions occurring in less than 
3% of the patients are unmarked.)<a href="#footnote-reference-2">†</a>See <a href="#section-7">WARNINGS</a>.<a href="#footnote-reference-3">‡</a>See <a href="#section-8">PRECAUTIONS</a>.<p><br></p>
<p>Other adverse reactions that have been reported with the individual 
components and within each category are listed in order of decreasing 
severity:</p>
<a href="http://"></a><a href="http://"></a>Amiloride<p><span>Body as a Whole:</span> Painful 
extremities, neck/shoulder <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">ache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigability</span>;</p>
<p><span>Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span>;</p>
<p><span>Digestive:</span> Activation of probable 
pre-existing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, abnormal liver function, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, 
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>;</p>
<p><span>Hematologic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, 
<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>;</p>
<p><span>Integumentary:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, dry 
mouth;</p>
<p><span>Nervous System/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span>, 
<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, decreased libido;</p>
<p><span>Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span>, 
<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>;</p>
<p><span>Special Senses:</span> Increased intraocular 
pressure, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>;</p>
<p><span>Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4090870" conceptname="Spasm of bladder">Bladder spasms</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, 
<span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>.</p>
<a href="http://"></a><a href="http://"></a>Hydrochlorothiazide<p><span>Digestive:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, 
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, gastric 
irritation;</p>
<p><span>Hematologic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, 
<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>;</p>
<p><span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>, 
necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> 
including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, 
<span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>;</p>
<p><span>Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span> (see <a href="#section-8">PRECAUTIONS</a>), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, 
<span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>;</p>
<p><span>Nervous System/Psychiatric:</span> 
<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>;</p>
<p><span>Special Senses:</span> Transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, 
<span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>;</p>
<p><span>Urogenital:</span> Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> (see <a href="#section-7">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No data are available in regard to overdosage in humans. The oral 
LD<span class="Sub">50</span> of the combination drug is 189 and 422 mg/kg for 
female mice and female rats, respectively.</p>
<p>It is not known whether the drug is dialyzable.</p>
<p>No specific information is available on the treatment of overdosage with 
amiloride and hydrochlorothiazide, and no specific antidote is available. 
Treatment is symptomatic and supportive. Therapy with amiloride and 
hydrochlorothiazide should be discontinued and the patient observed closely. 
Suggested measures include induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and/or gastric lavage.</p>
<a href="http://"></a><a href="http://"></a>Amiloride hydrochloride<p>No data are available in regard to overdosage in humans.</p>
<p>The oral LD<span class="Sub">50</span> of amiloride hydrochloride (calculated 
as the base) is 56 mg/kg in mice and 36 to 85 mg/kg in rats, depending on the 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.</p>
<p>The most common signs and symptoms to be expected with overdosage are 
<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>. If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> occurs, active measures 
should be taken to reduce the serum potassium levels.</p>
<a href="http://"></a><a href="http://"></a>Hydrochlorothiazide<p>The oral LD<span class="Sub">50</span> of hydrochlorothiazide is 
greater than 10 g/kg in both mice and rats.</p>
<p>The most common signs and symptoms observed are those caused by electrolyte 
depletion (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting 
from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> 
may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Amiloride HCl and hydrochlorothiazide tablets should be 
administered with food.</p>
<p>The usual starting dosage is 1 tablet a day. The dosage may be increased to 2 
tablets a day, if necessary. More than 2 tablets of amiloride hydrochloride and 
hydrochlorothiazide daily usually are not needed and there is no controlled 
experience with such doses. Hydrochlorothiazide can be given at doses of 12.5 to 
50 mg per day when used alone. Patients usually do not require doses of 
hydrochlorothiazide in excess of 50 mg daily when combined with other 
antihypertensive agents.</p>
<p>The daily dose is usually given as a single dose but may be given in divided 
doses. Once an initial <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> has been achieved, dosage adjustment may be 
necessary. Maintenance therapy may be on an intermittent basis.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Amiloride hydrochloride and hydrochlorothiazide tablets are 
available containing 5 mg of anhydrous amiloride hydrochloride and 50 mg of 
hydrochlorothiazide.</p>
<p>The tablets are scored, light orange, round tablets debossed with <span class="Bold">M577</span> on the scored side and the other side being blank. They 
are available as follows:</p>
<a name="i5650d1ea-be61-43ff-88ab-7918ef32314c"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-0667-1<br>
</td>
</tr>
<tr>
<td>Bottles of 90<br>
</td>
<td>NDC 54868-0667-2<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 100<br>
</td>
<td>NDC 54868-0667-0<br>
</td>
</tr>
</tbody></table>
<p></p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">STORE AT CONTROLLED ROOM TEMPERATURE 15°–30°C 
(59°–86°F).</span></p>
<p><span class="Bold">PROTECT FROM LIGHT.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a 
child-resistant closure.</p>
<a href="http://"></a><a href="http://"></a><p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REVISED MARCH 2003<br>AHCTZ:R11</p>
<br><br><span class="Bold">Relabeling and Repackaging by:<br></span>Physicians Total Care, Inc.<br>Tulsa, OK       74146<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Amiloride Hydrochloride and Hydrochlorothiazide tablets</p>
<p>5 mg/50 mg<br></p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71f5c703-94d4-49b0-9c2d-374b9cbcab85&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">amiloride hydrochloride and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-0667(NDC:0378-0577)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMILORIDE HYDROCHLORIDE</strong> (AMILORIDE) </td>
<td class="formItem">AMILORIDE HYDROCHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (Light Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;577</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-0667-0</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-0667-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-0667-2</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA073209</td>
<td class="formItem">05/16/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a6d988da-80ed-4d4c-9eec-36aeeb274aa7</div>
<div>Set id: 71f5c703-94d4-49b0-9c2d-374b9cbcab85</div>
<div>Version: 1</div>
<div>Effective Time: 20101117</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
